Please login to the form below
Rob Jones
This page shows the latest Rob Jones news and features for those working in and with pharma, biotech and healthcare.
Janssen’s Erleada combination accepted in Scotland for prostate cancer
cancer once it has spread outside the prostate,” said Professor Rob Jones, consultant in medical oncology and professor of clinical cancer research at the University of Glasgow. ... Jones added.
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
New faces at Lucid, 90Ten and Page & Page
Lucid Group has appointed Rob Apollo as its new Director of Corporate Development. ... Also bolstering the 90Ten Communications team is Rob Jones, who joins the team as an account director.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
90TEN gets 2019 off to a strong start with four new hires
Senior Account Director Ruth McIntyre, Account Director Rob Jones and Senior Account Manager Jack Dixey take up positions in 90TEN Communications, and Senior Account Director Niamh Mangan joins 90TEN Medical. ... Rob moves to 90TEN from the University of
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
